Cuba developed Soberana 02 against COVID-19

The Soberana 02 vaccine began its expanded phase II clinical trial this week, which will be extended to 900 people between 19 and 80 years of age, while in February a new test with pediatric population is planned, so that it can also be applied to the kids.